drugset
drugset / Trial / NCT05203692

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

NCT05203692 ↗

Phase 1 Completed 80 enrolled Daiichi Sankyo
RandomizedSequentialDouble-blindTreatment

Summary

This will be the first-in-human study designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of DS-7011a in healthy participants.

Timeline

Start
2022-02-02
Primary completion
2023-01-25
Completion
2023-03-22

Drugs

EvaluationDrugModalityDoseRoute
Subject DS-7011a Monoclonal antibody 0.1 mg/kg Intravenous

Indications

systemic lupus erythematosus